Summary
Zoetis Inc. reported solid financial results for the second quarter and first half of 2025. Revenue increased by 4% to $2.46 billion for the quarter and 3% to $4.68 billion for the first half, demonstrating continued growth driven by price increases and strong performance in key franchises, particularly in companion animal products. Diluted earnings per share also saw a significant increase, rising to $1.61 for the quarter and $3.02 for the half, up from $1.37 and $2.68 respectively in the prior year periods. This growth reflects effective cost management, including a reduction in the cost of sales as a percentage of revenue, and a strategic focus on higher-margin products. The company continues to navigate a dynamic global environment, with operational revenue growth outpacing reported growth due to unfavorable foreign exchange rates. Despite these headwinds, Zoetis maintains a strong financial position, evidenced by healthy operating cash flow and a robust balance sheet. The company also highlighted ongoing investments in research and development to fuel future innovation and maintain its leadership position in the animal health sector. Shareholder returns remain a priority, with continued share repurchases under its authorized program.
Financial Highlights
50 data points| Revenue | $2.46B |
| Cost of Revenue | $649.00M |
| Gross Profit | $1.81B |
| SG&A Expenses | $617.00M |
| Interest Expense | $53.00M |
| Net Income | $718.00M |
| EPS (Basic) | $1.61 |
| EPS (Diluted) | $1.61 |
| Shares Outstanding (Basic) | 445.10M |
| Shares Outstanding (Diluted) | 445.50M |
Key Highlights
- 1Total revenue for the second quarter of 2025 increased by 4% to $2.46 billion, with operational revenue growth of 5%.
- 2Diluted earnings per share for the second quarter of 2025 rose to $1.61, a 18% increase compared to $1.37 in the prior year period.
- 3For the first six months of 2025, revenue grew by 3% to $4.68 billion, and diluted EPS increased by 13% to $3.02.
- 4Companion animal products showed robust growth, with revenue up 8% for the quarter and 9% for the first six months, driven by key franchises like Simparica Trio and dermatology products.
- 5Cost of sales as a percentage of revenue improved to 26.4% in Q2 2025 from 28.3% in Q2 2024, benefiting from favorable impacts of divestitures, foreign exchange, and price increases.
- 6The company continued its share repurchase program, repurchasing approximately 2.14 million shares for $337 million during the quarter, with $4.9 billion remaining under its authorized program.
- 7Zoetis continues to invest in R&D, with R&D expenses remaining stable at $172 million for the quarter and decreasing slightly by 1% to $329 million for the first six months, supporting innovation and portfolio progression.